Reactogenicity of BNT162b2 mRNA COVID-19 Vaccine in a Young Working Age Population: A Survey among Medical School Residents, within a Mass Vaccination Campaign, in a Regional Reference Teaching Hospital in Italy

Vaccinations are a key prevention measure in fighting the COVID-19 pandemic. The BNT162b2 mRNA vaccine (BioNTech/Pfizer), the first to receive authorization, was widely used in the mass vaccination campaign in Italy. Healthcare workers were identified as a priority group for vaccination, but few stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahmani, Alborz, Dini, Guglielmo, Orsi, Andrea, Sticchi, Laura, Bruzzone, Bianca, Montecucco, Alfredo, Pellegrini, Luca, Manca, Alessia, Domnich, Alexander, Battistini, Angela, Kusznir Vitturi, Bruno, Zacconi, Sonia, Debarbieri, Nicoletta, Icardi, Giancarlo, Durando, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/
https://www.ncbi.nlm.nih.gov/pubmed/34835199
http://dx.doi.org/10.3390/vaccines9111269

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625320/
https://www.ncbi.nlm.nih.gov/pubmed/34835199
http://dx.doi.org/10.3390/vaccines9111269

Ejemplares similares